Cyprium Therapeutics focuses on the development of novel therapies treatment for Menkes disease and related copper metabolism disorders.
Cyprium Therapeutics has raised $4.1M in total funding. The most recent round was Grant. The last funding was announced in March 2024.
Cyprium Therapeutics's investors include National Institute of Neurological Disorders and Stroke.
Cyprium Therapeutics is headquartered in New York, United States.
Cyprium Therapeutics focuses on the development of novel therapies treatment for Menkes disease and related copper metabolism disorders.
Cyprium Therapeutics is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Cyprium Therapeutics — Funding & Investors." VCBacked, March 4, 2024, https://www.vcbacked.co/company/cyprium-therapeutics. Accessed November 14, 2026.
VCBacked. (2024). Cyprium Therapeutics — Funding & Investors. Retrieved November 14, 2026, from https://www.vcbacked.co/company/cyprium-therapeutics
{{cite web |title=Cyprium Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/cyprium-therapeutics |website=VCBacked |access-date=November 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at Cyprium Therapeutics? Request a listing update